Trial
NCT04855136
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
BB2121
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-11